Table 4.

Clinical characteristics and outcomes in patients with MRSA-BSI treated with ceftaroline.

Variable	No. of Patients a	%	95% CI
Characteristics of Ceftaroline Therapy
Empirical Therapy b	2/12	17	3–46
Targeted Therapy	10/12	83	54–97
First-Line Therapy	3/12	25	7–54
Salvage Therapy	9/12	75	46–93
Monotherapy	7/12	58	29–82
Combination Therapy c	5/12	42	18–71
Time to Ceftaroline Initiation in Days, Median (IQR)	6 (2–10)		2–10
Duration of Ceftaroline Therapy in Survivors, Median (IQR)	13 (11–14)		5–16
Type Of Infection
Isolated BSI	4/12	33	12–63
BSI With Metastatic Foci of Infection d	8/12	67	37–88
Early Source Control e
Performed or Unnecessary	7/12	58	29–82
No f	5/12	42	18–71
Follow-Up Cultures At 72 H After Ceftaroline Initiation
Follow-Up Cultures Performed	9/12	75	46–93
Microbiological Success g	6/9	67	32–90
Clinical Outcomes
Favorable Response at the End of Ceftaroline Therapy	8/12	67	37–88
Mortality at the End of Ceftaroline Therapy	2/12	17	3–46
28-Day Mortality	4/12	33	12–63

BSI, bloodstream infection; CI, confidence intervals; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus. ^a Results are presented as No. of patients/Total of patients unless otherwise indicated; ^b Etiological diagnosis made after ceftaroline initiation; ^c With other agents with anti-MRSA activity: daptomycin (n = 5); ^d Endocarditis (n = 3); pneumonia (n = 1), septic arthritis (n = 1), vertebral osteomyelitis (n = 1), pneumonia plus septic arthritis (n = 1), pneumonia plus vertebral osteomyelitis (n = 1); ^e Performed within 24 h from BSI onset (defined as the time when the first positive blood culture was drawn); ^f central venous catheter removed later than 24 h after BSI onset (n = 3), infective endocarditis deemed as inoperable by the cardiac surgeon (n = 2); ^g Defined as negative blood cultures at 72 h after ceftaroline initiation.